We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

100 hedge funds and large institutions have $579M invested in Aclaris Therapeutics in 2016 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 40 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

717% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 6

471% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 7

300% more funds holding in top 10

Funds holding in top 10: 2 → 8 (+6)

84% more ownership

Funds ownership: 0% → 84% (+84%)

72% more funds holding

Funds holding: 58 → 100 (+42)

46% more capital invested

Capital invested by funds: $396M → $579M (+$183M)

Holders
100
Holders Change
+42
Holders Change %
+72.41%
% of All Funds
2.5%
Holding in Top 10
8
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+300%
% of All Funds
0.2%
New
49
Increased
40
Reduced
7
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$21.2M
2
PC
PointState Capital
New York
+$18.3M
3
Invesco
Invesco
Georgia
+$15.9M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$11.5M
5
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$11.4M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$55.9M
2
RCM
RA Capital Management
Massachusetts
-$39.6M
3
VC
Vivo Capital
California
-$23.1M
4
Fidelity International
Fidelity International
Bermuda
-$4.85M
5
GTC
Ghost Tree Capital
New York
-$1.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
51
Charles Schwab
California
$1.12M +$426K +16,694 +68%
BIM
52
BlackRock Investment Management
Delaware
$1.06M +$108K +4,238 +12%
OAM
53
Oxford Asset Management
United Kingdom
$1.05M +$989K +38,781 New
RCAMU
54
Rothschild & Co Asset Management US
Connecticut
$1.05M +$986K +38,677 New
RHJA
55
Rice Hall James & Associates
California
$943K +$886K +34,734 New
Norges Bank
56
Norges Bank
Norway
$900K – – –
PPA
57
Parametric Portfolio Associates
Washington
$900K +$846K +33,174 New
Swiss National Bank
58
Swiss National Bank
Switzerland
$795K +$357K +14,000 +92%
AA
59
ALPS Advisors
Colorado
$663K +$623K +24,432 New
California State Teachers Retirement System (CalSTRS)
60
California State Teachers Retirement System (CalSTRS)
California
$632K +$81.6K +3,200 +16%
RSS
61
Rosenblum Silverman Sutton
California
$574K +$539K +21,150 New
CS
62
Credit Suisse
Switzerland
$524K +$491K +19,251 New
TA
63
Teachers Advisors
New York
$468K +$87.6K +3,435 +25%
New York State Common Retirement Fund
64
New York State Common Retirement Fund
New York
$425K +$36.6K +1,434 +10%
CC
65
Caxton Corporation
New Jersey
$359K +$338K +13,241 New
HCM
66
Highbridge Capital Management
New York
$355K +$334K +13,105 New
Neuberger Berman Group
67
Neuberger Berman Group
New York
$353K – – –
ARTA
68
A.R.T. Advisors
New York
$325K +$306K +12,000 New
AL
69
Airain Ltd
Guernsey
$320K +$300K +11,776 New
Citigroup
70
Citigroup
New York
$311K +$271K +10,617 +1,243%
Squarepoint
71
Squarepoint
New York
$291K +$274K +10,739 New
RhumbLine Advisers
72
RhumbLine Advisers
Massachusetts
$275K +$49.5K +1,940 +24%
FPC
73
Falcon Point Capital
California
$222K +$209K +8,183 New
MLICM
74
Metropolitan Life Insurance Company (MetLife)
New York
$219K – – –
Manulife (Manufacturers Life Insurance)
75
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$211K +$6.17K +242 +3%
1 2
3
4 5

ACRS Hedge Fund Activity: Q4 2016 in Review

100 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2016, worth a combined $579M — up 46% from $396M a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new ACRS positions and 6 closed out — a net gain of 43 holders — while 40 added to existing stakes and 7 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $21.2M. The largest seller was Fidelity Investments, cutting an estimated $55.9M.

  • 100 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2016, up from 58 in Q3 2016.
  • Funds reported $579M of Aclaris Therapeutics stock for Q4 2016, up 46% quarter-over-quarter.
  • 49 funds opened new Aclaris Therapeutics positions in Q4 2016 and 6 closed out, a net change of +43 holders.
  • The largest Aclaris Therapeutics buyer in Q4 2016 was Perceptive Advisors, an estimated $21.2M added.
  • The largest Aclaris Therapeutics seller in Q4 2016 was Fidelity Investments, an estimated $55.9M sold.

Based on aggregated 13F filings for Q4 2016.